On a U.S. moisturizer or cleanser, “dermatologist tested” suggests that a dermatologist was involved in testing. U.S. federal cosmetics rules specify no standard test for the phrase. The label alone leaves you with three unknowns: what the dermatologist did, who took part, and what the test found. Give the claim more weight when the brand can describe a test on the exact formula you’re buying and explain how the participants and the result relate to your concern. (FDA cosmetics labeling guidance).
Start with one question for the brand. Can you share a study summary for this exact product that describes the test, who completed it, and what reactions were recorded? A supervised test can show how a group tolerated the formula under specific conditions. The FDA does not grant approval through this kind of testing. Your own contact allergies require an individual assessment. (FDA’s overview of cosmetic approval).
What U.S. rules require
The FDA oversees cosmetic labeling and requires claims to be truthful and avoid misleading consumers. It does not approve cosmetic products or their labels before sale. Color additives generally require FDA approval for their intended use, with a statutory exception for coal-tar hair dyes. MoCRA’s facility registration and product listing duties do not change that: cosmetic products and their labeling still do not require FDA approval. (FDA on labeling claims and FDA on what it approves).
The related word “hypoallergenic” has a regulatory history of its own. The FDA says there is no federal definition for that term and recounts how a federal appeals court invalidated its 1975 rule that would have required comparative human testing for hypoallergenic claims. For “dermatologist tested,” the relevant point is broader. The FDA has no list of required safety tests for an individual cosmetic, so the evidence behind the claim depends on the test the company used. (FDA’s hypoallergenic cosmetics history and FDA’s cosmetic product testing guidance).
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) requires the responsible person, such as the manufacturer or distributor identified on the label, to ensure and keep records that adequately support product safety. According to the FDA, companies can use relevant existing safety data from scientifically robust methods. Those records are maintained by the company, and the FDA can access certain records under specified conditions. The law requires recordkeeping. If you want details about a particular claim, ask the company for a shareable summary. The legal duty to substantiate safety does not establish that a particular human trial was done. (FDA’s MoCRA summary).
The Federal Trade Commission’s advertising policy addresses the evidence behind objective claims. Advertisers must have a reasonable basis before an ad runs. If wording or surrounding claims convey a particular kind or level of evidence, the FTC expects support at that level. An ad that tells shoppers a dermatologist supervised testing in people with sensitive skin conveys a more specific claim than the shelf phrase alone. Read the whole package or product page when you decide what to ask the company to substantiate. (FTC advertising substantiation policy).
What one published moisturizer test measured
A human repeat insult patch test, or HRIPT, is one way to study irritation and sensitization under supervised conditions. Irritation is a local response to exposure. Sensitization is the process by which the immune system becomes able to react to a substance on later exposure. Repeated applications give investigators a chance to observe reactions that build with exposure. A later challenge, after a rest period, helps them look for a delayed reaction. Bormann and Maibach’s review found substantial variation and a lack of international standardization among published HRIPT protocols, so the test name alone leaves important details open. (Review of HRIPT protocols).
Stephanie J. Nisbet reported a six-week, open-label study of one lamellar moisturizer at a single center. GSK Consumer Healthcare funded the study and employed the author. Of the 233 adults who enrolled, 214 completed the study and received the final dermatological assessment. At scheduled clinic visits, semi-occlusive patches were applied to participants’ backs nine times over three weeks, with saline as a negative control. After two weeks without patches, the study team applied a challenge patch to a previously unexposed area. The researchers assessed that site at 48 and 72 hours after application. (Nisbet’s study methods and results).
The team graded skin reactions with the International Contact Dermatitis Research Group scale and set criteria for interpreting the findings in advance. The protocol specified cutoffs of at most 3% weak reactions or 2% strong reactions relative to applications for its irritancy assessment. Investigators treated an extreme-grade reaction as a potential allergy signal. Those thresholds describe how this study interpreted its clinical observations. For a shopper, the count of people who reacted and the severity of those reactions are more informative than a bare statement that the test met its cutoff. (Nisbet’s assessment criteria).
The report recorded one positive reaction at the moisturizer site during repeated exposure. One visit earlier, the same participant had shown an equivocal reaction to a different product on the shared multi-product patch, and the investigator stopped product application after the moisturizer reaction. The study could not identify the responsible ingredient. No reactions were detected among participants evaluated during the challenge phase. The authors interpreted the overall pattern as evidence of low irritation and sensitization potential for that formula under their test conditions. Keep the positive reaction and the completion count in view when reading a short summary of the study. (Nisbet’s reaction and completion data).
Which test details change your decision?
| Detail to check | What it tells you | How to weigh the result |
|---|---|---|
| Formula | A finished-product test addresses the mixture that was tested. A study on an individual ingredient or an earlier formula answers a narrower question. | Give the result less weight for this purchase if the company cannot link it to the version you are buying. |
| Participants | The people who took part and the reasons others were excluded determine how directly the result applies to you. | Treat the evidence as limited for your situation when the panel excluded people with your skin concern or the brand cannot describe who took part. |
| Endpoint | The endpoint is the outcome researchers measured, such as clinically graded irritation, a delayed reaction, or participant-reported stinging. Each answers a different question. | Look for an outcome that matches the concern driving your purchase. A result about redness gives limited information if you are trying to avoid stinging. |
| Comparator | Saline can help interpret a patch-site reaction. A claim of better tolerability than another moisturizer calls for a comparison that can answer that question. | Read a saline-controlled result as evidence from a patch study. Give a relative tolerability claim weight when the study directly tested the relevant comparison. |
| Exposure and follow-up | Repeated patches on the back and ordinary use on the face involve different sites, exposure patterns and follow-up. | Give the result more weight for daily use when the test conditions resemble the way you plan to use the product. |
In Nisbet’s study, participants had Fitzpatrick phototypes I–IV, with most in II or III. Fitzpatrick phototype describes how readily skin burns or tans with sun exposure. The investigators excluded people with active skin disease at the test site that could affect the results, and people with a history of severe allergic reactions to topical products. The authors explicitly left irritation and sensitization in phototypes V–VI unevaluated. If you’re looking for evidence in one of those groups or in people with active eczema, ask for the enrollment criteria and the findings for that group. A large overall panel can still leave your question open. (Nisbet’s eligibility criteria and limitations).
The exposure matters as much as the panel. A small area under a patch can reveal a reaction under controlled exposure, while a use study can describe what participants experienced when applying a product as directed. If your concern is stinging from a moisturizer used on your face, ask whether any study actually measured stinging at that site. In the published example, participant reports such as itching were noted qualitatively, while clinician-graded skin reactions were part of the formal assessment. (Nisbet’s clinical assessments).
Eight questions you can send to the brand
Send the full product name and version shown on the packaging. Ask for a public paper or a short methods-and-results summary. A useful reply lets you connect the package wording to the product, people and outcomes in the test. These questions work even if the company calls its study something other than an HRIPT.
Who ran the study, and what was the dermatologist’s role? Ask who supervised the study, who graded reactions, and who paid for it. Compare those roles with any claim that the evaluation was independent.
What test ran on this version? Ask whether the test used repeated patches, ordinary use, or another design, and whether the current finished formula was used.
How many people started and finished? Request both counts and the reasons people stopped, if available. A count of enrolled volunteers by itself leaves follow-up unclear.
Who qualified to take part? Ask how sensitive skin was defined if the brand makes that claim, and whether eczema, prior contact allergy, or particular phototypes were included or excluded.
What outcome counted as a reaction? Request the grading scale, any prespecified threshold, and the counts and severity of reactions. Ask separately about symptoms that participants reported if those matter to you.
What was the comparison? Ask whether there was a negative control, a competing formula, or a single group using the product. Each design answers a different question.
How long did exposure and follow-up last? Ask about the application site, exposure pattern and final reading. A short observation can miss a delayed reaction.
Can I read the methods and results? Ask for a paper, public report, or shareable summary with the test date and enough detail to connect the results to what appears on the package.
How to weigh the brand’s reply
Suppose a brand replies that a dermatologist supervised a finished-formula patch study and sends the methods, completion count, and reactions. If the panel resembles you and the measured outcome addresses your concern, you have a concrete reason to give the claim some weight. If it tested healthy back skin and your concern is how facial eczema responds to the formula, the same report gives you much less to go on. A different design, such as a facial use study that included people with your concern and recorded the symptoms you care about, could speak more directly to that question.
Read any headline number alongside the definition of a reaction and the point at which it was measured. In the published study, the challenge phase yielded zero observed reactions, while the earlier phase recorded a positive reaction at the moisturizer site. Both statements describe the same study. If a brand reports “zero reactions,” ask which phase it is referring to, whether the count includes people who withdrew, and whether the numbers describe people or individual applications. Those details tell you what was actually observed. (Nisbet’s reaction and completion data).
If the reply simply repeats “dermatologist tested” or gives a percentage without a denominator and a definition of the outcome, leave the claim out of your comparison. The study may exist and its data may be private. Your purchasing decision can rest on the information you can verify, including the ingredient list when you already know a specific allergen you need to avoid. A detailed study summary carries more weight when it gives enough information to check the actual claim, including any stronger promises on the product page.
When the question is a possible contact allergy
A product study observes a group exposed to a particular formula. Diagnostic patch testing helps a dermatologist investigate the cause of an individual’s rash. The American Academy of Dermatology describes applying selected allergens in patches, removing the patches after about 48 hours, and checking again around days four to seven for delayed reactions. The clinician chooses what to test and may consider further testing if the first series does not explain the rash. (American Academy of Dermatology on diagnostic patch testing).
If you keep reacting to skincare and don’t know the trigger, bring the product names and ingredient lists to a dermatologist and ask whether diagnostic patch testing fits your situation. Put a known allergen ahead of any reassuring label wording in your buying decision. The brand summary can help you judge the formula’s evidence. Your clinical history and any diagnostic findings address whether a specific substance is a problem for you.
Sources
U.S. Food and Drug Administration. Product Testing of Cosmetics.
U.S. Food and Drug Administration. “Hypoallergenic” Cosmetics.
U.S. Food and Drug Administration. Cosmetics Labeling Claims.
U.S. Food and Drug Administration. Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
U.S. Food and Drug Administration. Is It Really 'FDA Approved'?
Federal Trade Commission. FTC Policy Statement Regarding Advertising Substantiation.
Stephanie J. Nisbet, Journal of Cosmetic Dermatology (2019). Absence of human skin irritation and allergenic potential after repeated patch applications of a lamellar moisturizer.
Jordan L. Bormann and Howard I. Maibach, Regulatory Toxicology and Pharmacology (2021). Draize human repeat insult patch test (HRIPT): Seven decades of pitfalls and progress.
American Academy of Dermatology. Patch testing can find what's causing your rash.




